4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 30 September – 3 October 2018 / New York, NY / USA Jean-François Mayol attending
Entries by canvax
BIO International Convention 2018
BIO International Convention 2018 4-7 June 2018 / Boston, MA / USA Madiha Derouazi attending
ASCO Annual Meeting 2018
ASCO Annual Meeting 2018 1-5 June 2018 / Chicago, IL / USA Patricia Delaite attending
16th CIMT Annual Meeting
16th CIMT Annual Meeting 15-17 May 2018 / Mainz / Germany Jean-François Mayol attending
14th Annual PEGS Summit
14th Annual PEGS Summit 1-5 May 2018 / Boston, MA / USA Madiha Derouazi speaking
AACR Annual Meeting 2018
AACR Annual Meeting 2018 14-18 April 2018 / Chicago / Illinois Patricia Delaite and Elodie Belnoue attending
AMAL Therapeutics raises EUR 8 million (CHF 8.8 million) in first closing of Series B financing round
Geneva, Switzerland – 5 September 2017 – AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the first tranche of its Series B financing round, raising €8 million (CHF 8.8 million). View PDF
TOP 100 STARTUP AWARD 2016: on 14th September, Amal Therapeutics reached the top 10
Each year, startup.ch launches the TOP 100 STARTUP AWARD in cooperation with the Handelszeitung and PME Magazine. From over 100.000 young companies, the 100 most innovative and promising Swiss startups are picked by top startup experts. On Wednesday 14th September 2016, Amal Therapeutics reached the top10, and was elected at the rank number 8 by […]
Amal Therapeutics Wins 2d prize 2016 at Global Healthcare Innovation Academy (GHIA), Calgary
Amongst several applications within the four partner sites, 14 candidates have been shortlisted for the 2016 Global Healthcare Innovation Academy in Calgary. Amal Therapeutics represented by Jean-François Mayol, was selected in the top 6 innovations by the Grand Jury comprised of international and local experts in science, innovation, healthcare, business, IP and marketing. Amal Therapeutics […]
Amal Therapeutics to publish R&D outcomes in Molecular Therapy
Geneva, Switzerland, July 5, 2016 – Amal Therapeutics announced today that part of its recent research findings about the enhancement of anti-tumor immune responses through optimized combination of adjuvant and cellpenetrating peptide based-vaccines, is available on-line on the Molecular Therapy website on Tuesday July 5, 2016. View PDF
Amal Therapeutics SA
c/o Fondation pour Recherches Médicales
64 av. de la Roseraie
1205 Geneva
Switzerland
